Literature DB >> 8170550

Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination.

M Rodriguez1, W E Karnes, J D Bartleson, A A Pineda.   

Abstract

We present six patients with acute fulminant episodes of CNS inflammatory demyelination who responded to therapeutic plasmapheresis after failing a course of high-dose methylprednisolone administered IV. Neurologic improvement occurred in three of the patients following the second plasmapheresis. Dramatic improvement in motor function (four patients) and language (two patients) began within 2 to 14 days and persisted during the 6 to 35 months (mean, 15 months) of follow-up. Results of this uncontrolled study suggest that plasmapheresis in the absence of other immunosuppressive drugs may have a role in the treatment of severe episodes of inflammatory demyelination in a select subset of MS patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8170550     DOI: 10.1212/wnl.43.6.1100

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  24 in total

1.  Acute demyelinating disorders of the central nervous system.

Authors:  Meghan K Harris; Amir Hadi Maghzi; Masoud Etemadifar; Roger E Kelley; Eduardo Gonzalez-Toledo; Alireza Minagar
Journal:  Curr Treat Options Neurol       Date:  2009-01       Impact factor: 3.598

Review 2.  Isolated, relapsing and progressive demyelinating diseases of the central nervous system.

Authors:  Axel Petzold
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

Review 3.  Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.

Authors:  Bharath Wootla; Jens O Watzlawik; Nikolaos Stavropoulos; Nathan J Wittenberg; Harika Dasari; Murtada A Abdelrahim; John R Henley; Sang-Hyun Oh; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Opin Biol Ther       Date:  2016-03-10       Impact factor: 4.388

4.  Therapeutics to promote CNS repair: a natural human neuron-binding IgM regulates membrane-raft dynamics and improves motility in a mouse model of multiple sclerosis.

Authors:  Xiaohua Xu; Aleksandar Denic; Arthur E Warrington; Allan J Bieber; Moses Rodriguez
Journal:  J Clin Immunol       Date:  2012-09-19       Impact factor: 8.317

5.  Plasma Exchange in a Patient with Tumefactive, Corticosteroid-Resistant Multiple Sclerosis.

Authors:  Kristin M Ikeda; Donald H Lee; J Alexander Fraser; Seyed Mirsattari; Sarah A Morrow
Journal:  Int J MS Care       Date:  2015 Sep-Oct

6.  Therapeutic Plasma Exchange in Neurologic Diseases: An Experience with 91 Patients in Seven Years.

Authors:  Sibel Karaca; İlknur Kozanoğlu; Başak Karakurum Göksel; Mehmet Karataş; Meliha Tan; V Deniz Yerdelen; Semih Giray; Zülfikar Arlier
Journal:  Noro Psikiyatr Ars       Date:  2014-03-01       Impact factor: 1.339

Review 7.  Multiple sclerosis: a unique immunopathological syndrome of the central nervous system.

Authors:  S F Hunter; M Rodriguez
Journal:  Springer Semin Immunopathol       Date:  1995

8.  Beneficial plasma exchange response in central nervous system inflammatory demyelination.

Authors:  Setty M Magaña; B Mark Keegan; Brian G Weinshenker; Bradley J Erickson; Sean J Pittock; Vanda A Lennon; Moses Rodriguez; Kristine Thomsen; Stephen Weigand; Jay Mandrekar; Linda Linbo; Claudia F Lucchinetti
Journal:  Arch Neurol       Date:  2011-03-14

Review 9.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

Review 10.  Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.

Authors:  J Nicholas Brenton; Brenda L Banwell
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.